Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Humanigen, Inc. (HGEN)

0.137   0.002 (1.56%) 03-24 16:00
Open: 0.1369 Pre. Close: 0.1349
High: 0.1391 Low: 0.1311
Volume: 317,038 Market Cap: 16(M)

Technical analysis

as of: 2023-03-24 4:26:42 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.17     One year: 0.19
Support: Support1: 0.1    Support2: 0.09
Resistance: Resistance1: 0.14    Resistance2: 0.17
Pivot: 0.14
Moving Average: MA(5): 0.13     MA(20): 0.14
MA(100): 0.15     MA(250): 0.8
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 22.5     %D(3): 35.2
RSI: RSI(14): 41.4
52-week: High: 3.39  Low: 0.09
Average Vol(K): 3-Month: 3,512 (K)  10-Days: 1,019 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HGEN ] has closed above bottom band by 18.2%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.14 - 0.14 0.14 - 0.14
Low: 0.13 - 0.13 0.13 - 0.13
Close: 0.14 - 0.14 0.14 - 0.14

Company Description

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Headline News

Fri, 24 Mar 2023
Is Humanigen Inc (HGEN) Stock a Good Value Friday? - InvestorsObserver

Fri, 24 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com

Wed, 22 Mar 2023
Humanigen Inc. (HGEN) Shares Down Despite Recent Market ... - The News Heater

Wed, 22 Mar 2023
Is Humanigen Inc. (NASDAQ: HGEN) Worth Your Money In 2023? - Marketing Sentinel

Fri, 17 Mar 2023
North American Morning Briefing : Focus on Bank -2- - Marketscreener.com

Thu, 02 Mar 2023
Is it Time to Dump Humanigen Inc (HGEN) Stock After it Has Fallen 6.25% in a Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 119 (M)
% Held by Insiders 1.1013e+008 (%)
% Held by Institutions 11.9 (%)
Shares Short 5,780 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 151.5
Return on Equity (ttm) -126.3
Qtrly Rev. Growth 3.33e+006
Gross Profit (p.s.) 0
Sales Per Share 0.04
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -94 (M)

Stock Valuations

PE Ratio 0
PEG Ratio -0.1
Price to Book value 0
Price to Sales 2.83
Price to Cash Flow 0.25

Stock Dividends

Dividend 0
Forward Dividend 7.24e+006
Dividend Yield 0%
Dividend Pay Date 2020-09-13
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.